mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs.

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Contact us

Phone

+7 (495) 726-52-53

Email

info@hepatera.ru

Hepatera is a Russian biotechnology company founded in 2011. The main activity of the company is the search for and evaluation of promising drug candidates, as well as development and bringing to the Russian market safe and effective drugs for the treatment of liver diseases. First product (Myrcludex B) is aimed at the treatment of chronic hepatitis B and D.

Maxwell Biotech Group

12/19, build.1, Verkhnyaya Radishchevskaya str. Moscow, 109240, Russia

Your Name (required)

Your Email (required)

Subject

Your Message